Skip to main content
VaccineWatch
VaccinesSymptomsStatesAnalysisToolsDashboardCompare

VaccineWatch

Transparent access to VAERS data for informed decision-making. We present the data as-is, with appropriate context and disclaimers.

Explore Data

  • Vaccines
  • Symptoms
  • Manufacturers
  • States
  • Dashboard
  • Compare Tool
  • Search

Deep Dives

  • The Denominator Problem
  • Onset Timing
  • Lot Number Analysis
  • COVID Impact
  • Myocarditis
  • Death Reports
  • Interactive Tools
  • All 23 Articles →

Resources

  • About
  • Methodology
  • FAQ
  • Glossary
  • Side Effects Guide
  • Vaccine Schedule
  • Vaccine Safety
  • Safety Timeline
  • Adverse Events
  • Is VAERS Reliable?
  • Report an Event
  • Disclaimer
  • VAERS Official Site ↗

Sister Sites

  • OpenMedicaid
  • OpenFeds
  • OpenSpending
  • OpenMedicare
  • OpenLobby
  • TheDataProject.ai

Data source: VAERS (Vaccine Adverse Event Reporting System)

Data through 2026 · Updated quarterly

Built by TheDataProject.ai · © 2026 VaccineWatch

Important: VAERS accepts reports of adverse events following vaccination. For any given report, there is no certainty that the reported event was caused by the vaccine. Reports may contain information that is incomplete, inaccurate, coincidental, or unverifiable. Most reports to VAERS are voluntary, which means they are subject to biases. This data cannot be used to determine if vaccines cause or contribute to adverse events.

⚠️

Important: VAERS reports alone cannot determine if a vaccine caused an adverse event. Reports may contain incomplete, inaccurate, or unverified information. Correlation does not equal causation.

  1. Home
  2. Side Effects
  3. Guillain-Barré Syndrome
8 min read
Share

Guillain-Barré Syndrome & Vaccines

Guillain-Barré Syndrome (GBS) is a rare neurological condition where the immune system attacks the peripheral nerves. It has a small but established association with certain vaccines — here's what the data shows.

Background Rate
1-2 per 100,000
Annual incidence, all causes
Vaccine-Associated Risk
1-2 extra per million
Above background, for associated vaccines
Recovery
~85% recover
Full or near-full recovery

What Is GBS?

Guillain-Barré Syndrome causes the immune system to attack the myelin sheath surrounding peripheral nerves. Symptoms include:

  • Weakness and tingling in the legs, often spreading upward
  • Difficulty walking or climbing stairs
  • Facial weakness or paralysis
  • Difficulty with eye movements or vision
  • Severe pain
  • In severe cases, difficulty breathing (requiring ventilation)

GBS is most commonly triggered by infections — especially Campylobacter jejuni bacteria, influenza, cytomegalovirus, and Epstein-Barr virus. The vaccine association is much smaller than the infection association.

Vaccines Associated with GBS

Influenza (Flu) Vaccine

The most established vaccine-GBS association. Studies estimate approximately1-2 additional GBS cases per million flu vaccine doses. This was first identified during the 1976 swine flu vaccination campaign, which had a higher rate (~1 per 100,000). Modern flu vaccines have a much smaller risk.

Importantly, influenza infection itself carries a higher GBS risk than the vaccine — about 17 times higher per the CDC. So vaccination actually reduces your overall GBS risk by preventing the flu.

Johnson & Johnson (Janssen) COVID-19 Vaccine

The J&J/Janssen COVID-19 vaccine was found to have a small increased risk of GBS, estimated at about 8 cases per million doses in the first 6 weeks. This was one factor in the CDC's preference recommendation for mRNA vaccines (Pfizer, Moderna) over J&J. J&J is no longer available in the U.S.

mRNA COVID-19 Vaccines (Pfizer, Moderna)

Studies have generally not found an increased GBS risk with mRNA COVID vaccines. The adenoviral vector mechanism in J&J appears to be the relevant factor, not COVID vaccination in general.

GBS Treatment and Outcomes

  • Treatment: Immunoglobulin therapy (IVIG) or plasma exchange (plasmapheresis)
  • Recovery: About 85% of patients recover fully or nearly fully
  • Timeline: Recovery can take weeks to months; some residual weakness may persist
  • Mortality: About 3-5% of cases are fatal, usually from respiratory complications

VAERS and GBS

VAERS contains reports of GBS after various vaccines. As with all VAERS data, these are reports of temporal association — not confirmed causation. The established associations described above come from large epidemiological studies, not from VAERS alone.

GBS is on the Vaccine Injury Table, meaning that GBS occurring within a defined time window after certain vaccines is eligible for compensation through theVaccine Injury Compensation Program.

Should You Still Get Vaccinated?

For most people, yes. The risk of GBS from vaccination is extremely small (1-2 per million) and the risk of GBS from the infections that vaccines prevent is typically higher. However, people who have had GBS within 6 weeks of a previous vaccine dose should discuss future vaccination with their neurologist.

Explore the Data

GBS in VAERS →
Reports by vaccine
Flu Vaccine Side Effects →
Including GBS context
Vaccine Injuries →
VICP compensation

Related

Myocarditis
Heart inflammation
Allergic Reactions
Anaphylaxis data
Death Reports
Mortality data